Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program

BACKGROUND: Volasertib (BI 6727) is a potent inhibitor of Polo-like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines. Because of its novel mechanism of action, volasertib was evaluated through the PPTP. PROCEDURES: Volasertib was tested against the PPTP in vitro cel...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pediatr Blood Cancer
Auteurs principaux: Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Lock, Richard, Billups, Catherine A., Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4241497/
https://ncbi.nlm.nih.gov/pubmed/23956067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24616
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires